Erythropoietic Protoporphyria (EPP)
A rare inherited disorder of heme production that causes severe pain and burning of the skin within minutes of sun exposure, with specialist care helping patients manage symptoms and protect liver health.
- Genetic counseling guidance
- Photoprotection planning
- Liver health monitoring
- Estimated Prevalence
- ~1 in 75,000โ200,000
- Typical Onset
- Early childhood
- Primary Gene
- FECH (or ALAS2 in XLP)
- Advanced Option
- Afamelanotide Therapy
Condition Overview
Erythropoietic Protoporphyria (EPP) is a rare inherited disorder of heme biosynthesis in which protoporphyrin IX accumulates in red blood cells, plasma, and skin. When skin exposed to sunlight absorbs this excess protoporphyrin, it triggers a phototoxic reaction that causes intense burning, swelling, and pain, typically within minutes of light exposure.
EPP usually presents in early childhood, often misdiagnosed initially as sun allergy or idiopathic photosensitivity, because the reaction is painful rather than itchy and visible skin changes can be subtle. Accurate diagnosis matters because it allows families to put photoprotection strategies in place early, monitor for the rare but serious complication of liver disease, and access emerging therapies designed specifically for this condition.
Types and Subtypes
EPP is classified by the underlying genetic defect and inheritance pattern, both of which influence severity and management.
Symptoms and Signs
Symptoms are triggered specifically by visible light, not just UV rays, which distinguishes EPP from many other photosensitivity disorders.
Causes and Risk Factors
EPP arises from inherited defects in the heme biosynthesis pathway that lead to excess accumulation of protoporphyrin IX, which is intrinsically phototoxic.
Diagnosis and Investigations
Diagnosis combines a careful history of light-triggered pain with biochemical confirmation and, where available, genetic testing.
Disease Severity and Risk Stratification
EPP is not staged like cancer, but clinicians stratify patients by photosensitivity severity and liver risk to guide monitoring intensity.
Standard Treatment Options
There is no cure for EPP; management centers on strict photoprotection and monitoring, with medical therapy available to extend sunlight tolerance.
Advanced & Emerging Therapies
Targeted therapy now exists for EPP, marking a shift from photoprotection alone toward biologically directed treatment.
Melanocortin Receptor Agonist
Afamelanotide
An implant that stimulates melanin production to increase tolerance to light exposure, approved in several countries for adults with EPP.
Investigational Pathway Modulation
Heme pathway-targeted agents
Research is exploring agents that reduce protoporphyrin accumulation upstream in the heme synthesis pathway.
Liver-Directed Care
Specialist hepatology coordination
For patients with hepatic involvement, coordinated care with hepatology and, rarely, liver transplant evaluation in advanced disease.
Biomarkers & Precision Medicine
Porphyrin and liver-related biomarkers guide both diagnosis and ongoing monitoring in EPP.
When a Second Opinion May Be Important
Because EPP is rare, a second specialist opinion can help confirm the diagnosis and refine an individualized management plan.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Most people with EPP have a normal life expectancy, with quality of life shaped mainly by how well photosensitivity is managed and whether liver involvement develops.
Supportive Care and Living With EPP
Living well with EPP involves practical daily adaptations alongside medical follow-up.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients and families with Erythropoietic Protoporphyria connect with specialists experienced in porphyria management and coordinate report review for an informed second opinion.
Get a free case reviewFrequently Asked Questions
It is a rare inherited disorder in which excess protoporphyrin builds up in the skin and blood, causing painful reactions to sunlight.
Most cases are caused by mutations in the FECH gene, with a smaller subset caused by ALAS2 gene variants leading to X-linked protoporphyria.
EPP reactions are driven by visible light, not just ultraviolet rays, so standard UV-blocking sunscreens may offer limited protection.
A minority of patients develop protoporphyric liver disease, which is why periodic liver monitoring is recommended.
Afamelanotide, a melanocortin receptor agonist, is approved in some countries to increase sunlight tolerance in adults with EPP.
Yes, classic EPP usually requires inheriting a severe FECH mutation along with a common low-expression FECH variant; X-linked protoporphyria follows X-linked inheritance.
Yes, symptoms often begin in early childhood and may initially be mistaken for sun allergy.
Diagnosis relies on elevated erythrocyte protoporphyrin levels, plasma fluorescence testing, and genetic confirmation.
Diet does not cure EPP, but iron status and overall nutrition are sometimes assessed as part of a broader management plan.
Yes. CancerFax can help you organize medical reports and porphyrin test results for specialist review, coordinate a second opinion, and connect you with centers experienced in advanced porphyria therapies.
Considering a Specialist Review for EPP?
Send your porphyrin test results and genetic report so a specialist can help refine your management plan.